Related Experiment Videos
Ras/Raf signalling and emerging pharmacotherapeutic targets
1The Beatson Institute for Cancer Research, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow, UK. wkolch@beatson.gla.ac.uk
Abstract:
The Ras-Raf-MEK-ERK pathway is a ubiquitously expressed signalling module that regulates the proliferation, differentiation and survival of cells. This pathway features several oncogenes and is deregulated in approximately 30% of all human cancers. Thus, it has emerged as a prime target for antitumour therapy. Drugs targeting Ras, Raf or MEK are currently in clinical trials. They comprise vaccines, isoprenylation inhibitors, antisense compounds and kinase inhibitors. Most are remarkably well tolerated and some show promising efficacy. However, it is not clear which components of this pathway should be targeted and how maximum efficacy can be achieved. This paper reviews the current efforts with an emphasis on new mechanistic and conceptual approaches.
Insights
The Ras-Raf-MEK-ERK pathway is crucial for cell functions and frequently altered in cancers, making it a key target for new antitumour therapies. Research is exploring optimal strategies for targeting this pathway to maximize treatment efficacy.
Area of Science:
- Molecular Biology
- Cell Signaling
- Oncology
Background:
- The Ras-Raf-MEK-ERK pathway regulates fundamental cellular processes like proliferation, differentiation, and survival.
- This signaling module is implicated in approximately 30% of human cancers due to the presence of oncogenes.
- Its critical role in cancer pathogenesis makes it a significant target for therapeutic intervention.
Purpose of the Study:
- To review current therapeutic strategies targeting the Ras-Raf-MEK-ERK pathway.
- To discuss new mechanistic and conceptual approaches for optimizing antitumour therapy.
- To address the challenges in identifying the most effective targets within this pathway.
Main Methods:
- Review of current clinical trials and drug development efforts.
- Analysis of mechanistic data for pathway components.
- Conceptual evaluation of targeting strategies.
Main Results:
- Several drugs targeting Ras, Raf, or MEK are in clinical trials, including vaccines, kinase inhibitors, and antisense compounds.
- Many investigational drugs demonstrate good tolerability and promising efficacy.
- Optimal targeting strategies and component selection remain areas for further investigation.
Conclusions:
- The Ras-Raf-MEK-ERK pathway is a validated target for cancer therapy.
- Ongoing research focuses on refining treatment approaches for enhanced efficacy.
- Further studies are needed to determine the best targets and combination strategies.